Form 8-K - Current report:
SEC Accession No. 0001558370-22-015087
Filing Date
2022-10-19
Accepted
2022-10-19 16:50:41
Documents
13
Period of Report
2022-10-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krbp-20221013x8k.htm   iXBRL 8-K 54370
2 EX-10.1 krbp-20221013xex10d1.htm EX-10.1 281582
  Complete submission text file 0001558370-22-015087.txt   510897

Data Files

Seq Description Document Type Size
3 EX-101.SCH krbp-20221013.xsd EX-101.SCH 3042
4 EX-101.LAB krbp-20221013_lab.xml EX-101.LAB 16580
5 EX-101.PRE krbp-20221013_pre.xml EX-101.PRE 10533
7 EXTRACTED XBRL INSTANCE DOCUMENT krbp-20221013x8k_htm.xml XML 5105
Mailing Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054
Business Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054 832-968-4888
Kiromic Biopharma, Inc. (Filer) CIK: 0001792581 (see all company filings)

EIN.: 464762913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39619 | Film No.: 221319082
SIC: 2836 Biological Products, (No Diagnostic Substances)